Esperion Therapeutics News and Activities
Presence
Esperion Therapeutics develops and sells medicines for lowering cholesterol and reducing cardiovascular risk. Its products and support services serve patients, physicians, pharmacies, and health systems.
Esperion Therapeutics products and services overview:
- Cholesterol medicines
- Cardiovascular therapies
- Prescription drug sales
- Patient support services
Revenue: ~$320 million
Employees: 300
Headquarters: Ann Arbor, United States (USA)
Esperion Therapeutics is one of the...
Esperion Therapeutics is a company listed under the stock ticker ESPR (US).
Acquisition, funding and merger involving Esperion Therapeutics.
- Esperion Therapeutics has announced the acquisition of Corstasis (posted on March 5 2026).
Executives
View the org chart displaying its 24 main executives
Most searched biographies at Esperion Therapeutics
- Sheldon Koenig, President, Chief Executive Officer and Director
- Stephen Rocamboli, Director
- Martin Carroll, Director
Popular executive movements at Esperion Therapeutics
- John Harlow will join the company as Chief Commercial Officer on Nov. 17, 2025 (posted on November 5 2025).
Create your alert
to follow the executive moves at Esperion Therapeutics.
Biotechnology
Esperion Therapeutics has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- Laboratoire Servier has announced the acquisition of Edgewise Therapeutics (posted on June 4 2026).
- Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
Popular contacts in Biotechnology
News
Press releases by Esperion Therapeutics
- Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update | Esperion Therapeutics, Inc.
- Esperion Announces Establishment of Scientific Advisory Board to Support Pipeline and Life Cycle Management | Esperion Therapeutics, Inc.
- Esperion to Report Second Quarter 2022 Financial Results August 2, 2022 | Esperion Therapeutics, Inc.
- Real World Data Analysis Reveals Nearly Half of All Adults at High Risk for ASCVD and Eligible for a Statin Were Not On Any Statin | Esperion Therapeutics, Inc.
- Esperion to Participate in the 2022 Jefferies Global Healthcare Conference | Esperion Therapeutics, Inc.
- Esperion Announces the Appointment of J. Martin Carroll to its Board of Directors | Esperion Therapeutics, Inc.
- Esperion Announces Five Abstracts Accepted for Presentation at the National Lipid Association Scientific Sessions | Esperion Therapeutics, Inc.
- Esperion to Participate in Upcoming H.C. Wainwright Global Investment Conference | Esperion Therapeutics, Inc.
- Esperion Reports First Quarter 2022 Financial Results and Provides Company Update | Esperion Therapeutics, Inc.
- Esperion Announces Publication of CLEAR Harmony Open-Label Extension Study Data for Bempedoic Acid in the American Journal of Cardiology | Esperion Therapeutics, Inc.
- View more press releases Close
Social media about Esperion Therapeutics
- Esperion Therapeutics on Wikipedia, Google News & Yahoo Finance
- Esperion Therapeutics on LinkedIn, X (Twitter) & YouTube
